[Peptide hormones LH, FSH, TSH, prolactin, beta-HCG and PTH in patients with urogenital tumors].
Serum levels of the peptide hormones, LH, FSH, TSH, prolactin, beta-HCG and PTH are observed to significantly modulate in patients with urogenital tumors, beta-HCG appears elevated in patients with chorioncarcinoma, teratoma and embryonal carcinoma and is shown to increase serum prolactin. TSH and prolactin are measured in pathological range in patients with renal carcinomas. Following nephrectomy serum TSH persists in high levels only in patients with advanced diseases, while PTH is more frequently suppressed in these patients. Serum LH and prolactin show a more distinct change of values in infiltrating bladder cancer, when compared to that of noninvasive bladder carcinomas. Prostate benign hyperplasia and cancer demonstrate similar ranges for peptide hormones, that will be changed by estrogen treatment in its LH, TSH and prolactin pattern. Serum levels of peptide hormones are affected by a complex system of ectopic hormone production, synthesis of peptide analogues, metabolic changes due to age and treatment.
D006063:Chorionic Gonadotropin / Q000097:blood*; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood*; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood*; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood*; D011388:Prolactin / Q000097:blood*; D013972:Thyrotropin / Q000097:blood*; D014565:Urogenital Neoplasms / Q000097:blood*
D006063:Chorionic Gonadotropin; D010281:Parathyroid Hormone; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D013972:Thyrotropin
Peptidhormone LH, FSH, TSH, Prolaktin, beta-HCG und PTH bei Patienten mit urogenitalen Tumoren.